HelpAcademyLoginJoin us as a Member

InMed Pharmaceuticals Inc.

Sign in to save InMed Pharmaceuticals Inc. to a watchlist Sign in to set an alert for InMed Pharmaceuticals Inc.
Tickers
INM
Headquarters
Not recorded
SEC CIK
0001728328
Website
Not recorded

Closing prices

Latest close, 1.63

Closing prices for INM249 stored closes for INM from 3 Nov 2025 to 29 Oct 2026. Lowest 0.62 on 30 Mar 2026, highest 1.85 on 3 Nov 2025, latest 1.63 on 29 Oct 2026.Close0.501.001.502.003 Nov 20251 May 202629 Oct 2026
249 stored closes, oldest first. End of day, not intraday.

Source: Massive Closing prices as of End-of-day prices, not live

Massive Basic, non-business use; display licence needed before launch (D-1). Marketstack is kept as the backup source.

Not investment advice. End-of-day closing prices, not live quotes.

Drugs

No drugs from this company are tracked yet.

FDA-approved applications

No Drugs@FDA application has a sponsor name that matches this company.

Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.

Catalysts

No catalysts yet. Editors add each date together with its source.

Deals

No approved deals involve this company yet.

Reported fundamentals (SEC XBRL)

Latest value of each metric as reported to the SEC
MetricReported valuePeriodFiling
Revenue820,188 USD 1 Oct 2025 to 31 Dec 2025 FY2026 Q210-Q for Revenue on sec.gov (opens in a new tab)Filed
Net income (loss)−1,722,866 USD 1 Jan 2024 to 31 Mar 2024 FY2025 Q310-Q for Net income (loss) on sec.gov (opens in a new tab)Filed
Research and development expense630,636 USD 1 Oct 2025 to 31 Dec 2025 FY2026 Q210-Q for Research and development expense on sec.gov (opens in a new tab)Filed
Operating expenses2,286,796 USD 1 Oct 2025 to 31 Dec 2025 FY2026 Q210-Q for Operating expenses on sec.gov (opens in a new tab)Filed
Cash and cash equivalents6,954,834 USD At 31 Dec 2025 FY2026 Q210-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed
Short-term investments and marketable securities42,675 USD At 31 Dec 2025 FY2026 Q210-Q for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed
Total liabilities1,603,820 USD At 31 Dec 2025 FY2026 Q210-Q for Total liabilities on sec.gov (opens in a new tab)Filed
Stockholders' equity11,104,650 USD At 31 Mar 2024 FY2025 Q310-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed
Common shares outstanding (cover page)5,493,735 shares At 2 Sep 2026 FY202610-K for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed

History

Revenue, newest period first
PeriodReported valueFiling
1 Oct 2025 to 31 Dec 2025 FY2026 Q2820,188 USD10-Q filed 11 Feb 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2025 to 30 Sep 2025 FY2026 Q11,120,121 USD10-Q filed 6 Nov 2025 on sec.gov (opens in a new tab)Filed
1 Jul 2024 to 30 Jun 2025 4,942,633 USDS-4 filed 2 Jul 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Mar 2025 FY2025 Q31,261,578 USD10-Q filed 12 May 2025 on sec.gov (opens in a new tab)Filed
1 Oct 2024 to 31 Dec 2024 FY2026 Q21,111,707 USD10-Q filed 11 Feb 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2024 to 30 Sep 2024 FY2026 Q11,264,638 USD10-Q filed 6 Nov 2025 on sec.gov (opens in a new tab)Filed
1 Jul 2023 to 30 Jun 2024 4,597,730 USDS-4 filed 2 Jul 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2024 to 31 Mar 2024 FY2025 Q31,172,601 USD10-Q filed 12 May 2025 on sec.gov (opens in a new tab)Filed

The newest 12 periods of each metric are listed; older ones are on sec.gov.

Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.

Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read

SEC filings

SEC filings from InMed Pharmaceuticals Inc., newest first
FormFiledWhat it coversDocument
424B3 Form 424B3 View Form 424B3 filed 28 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-436382 (opens in a new tab)
4 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 27 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001940272-26-000028 (opens in a new tab)
4Event 16 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 20 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001940272-26-000026 (opens in a new tab)
4Event 13 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 15 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001940272-26-000025 (opens in a new tab)
4Event 6 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 8 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001940272-26-000023 (opens in a new tab)
4Event 1 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 5 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001940272-26-000022 (opens in a new tab)
424B3 Form 424B3 View Form 424B3 filed 1 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-410691 (opens in a new tab)
8-KEvent 16 Sep 2026 Current report (8-K)
  • Notice of delisting or listing rule failure (Item 3.01)
  • Other events (Item 8.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 18 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-101492 (opens in a new tab)
4Event 14 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 16 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001940272-26-000021 (opens in a new tab)
10-KEvent 30 Jun 2026 Annual report (10-K) View Annual report (10-K) filed 9 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-098419 (opens in a new tab)

Source: SEC EDGAR. Each row links to the filing on sec.gov.

Related news

No recent headlines mention this company.

Insider transactions

All rows for InMed Pharmaceuticals Inc. on Insider Trades

Last 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).

Buys code P
3 transactions, 91,101 shares, $118,062.85
Sells code S
None in this period
Other all other codes
None in this period

Last transaction:

Insider filings are public records and are not a recommendation. Source: SEC EDGAR.

Sources

Nothing on this page is investment advice.